Yang et al. reported that after 12 weeks of treatment with pioglitazone or metformin, pioglitazone was superior to metformin for decreasing RBP4 levels and HOMA-IR in patients with T2DM complicated with NAFLD [124]. The gene discussed is RBP4; the disease is type 2 diabetes mellitus.